Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198947 | 0.96 | PTGS2 (0.50) | PTGS2PTGS1SLC6A3SLC6A2NPC1 | |
| SCHEMBL1485942 | 0.77 | FGF23 (0.46) | PTGS2SLC6A3SLC6A2NPC1RAB9A | |
| SCHEMBL4282335 | 0.71 | SLC6A3 (0.64) | PTGS2PTGS1SLC6A3SLC6A2 | |
| Sulfamide SCHEMBL4639068 | 0.71 | PTGS2 (0.70) | PTGS2PTGS1SLC6A3CYP1A2LMNA | |
| SCHEMBL215545 | 0.71 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8656566 | 0.69 | PTGS2 (0.60) | PTGS2PTGS1SLC6A3SLC6A2NPC1 | |
| SCHEMBL1958644 | 0.69 | PTGS2 (0.50) | PTGS2PTGS1SLC6A3SLC6A2KDM4E | |
| SCHEMBL1957330 | 0.69 | SLC6A3 (0.46) | PTGS2PTGS1SLC6A3SLC6A2NOTUM | |
| SCHEMBL435618 | 0.69 | LMNA (0.44) | PTGS2PTGS1SLC6A3NPC1RAB9A | |
| SCHEMBL31371097 | 0.68 | LMNA (0.50) | PTGS2PTGS1SLC6A3SLC6A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188088-B2 | Ethenyl carboxamide derivatives useful as microbiocides | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-20090318495-A1 | ETHENYL CARBOXAMIDE DERIVATIVES USEFUL AS MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318495-A1 | ETHENYL CARBOXAMIDE DERIVATIVES USEFUL AS MICROBIOCIDES | CD14, MSR1, ELANE | PTGS2 938/4885PTGS1 747/4885SLC6A3 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.